CD274 and non-small cell lung carcinoma: Following this, subsequent Phase 3 trials have illustrated the efficacy of ICI combination treatments in patients with advanced NSCLC, regardless of PD‐L1 expression levels [29, 30, 31, 32, 40, 48, 49, 50, 69].